Please assess the completion status of the following clinical trial:

Trial Title: Molecular Signature of Valproic Acid in Breast Cancer With Functional Imaging Assessment - a Pilot

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Biopsy-proven invasive adenocarcinoma of the breast 1.5cm or larger by clinical exam or imaging including ultrasound, mammogram, CT, or MRI~2. Females at least 18 years-old,~3. Not pregnant, as demonstrated by a negative serum or urine pregnancy test in women of child bearing potential, and not planning on becoming pregnant~4. Willing to have a biopsy at the start of study if adequate sample for gene array is not available.~5. Willing to have a biopsy at the end of the trial if breast surgery is not planned.~6. ECOG Performance status 0-2~7. Able to provide informed consent and have signed an approved consent form that conforms to federal and institutional guidelines~Exclusion Criteria:~1. Need for immediate chemotherapy as determined by the patients' physicians, e.g., present or imminent compromise of vital organs or unacceptable symptoms from the tumor.~2. Known hypersensitivity to valproic acid or its components or peanut allergy~3. Inadequate bone marrow, kidney, and liver function (greater than grade 1 by CTCAE version 4) as defined by the protocol.~4. Immunocompromised due to medications or HIV as documented in medical history~5. Use of other antiepileptics or medications with known interactions with valproic acid (See protocol for full list)~6. Inborn errors of metabolism (valproic acid is contraindicated in patients with known urea cycle disorders)~7. History of pancreatitis~8. Use of a ketogenic diet~9. Inability to have an MRI due to extreme claustrophobia, possible metal fragments in the eye, cardiac pacemaker, implanted cardiac defibrillator, aneurysm clips, carotid artery vascular clamp, neurostimulator, insulin or infusion pump, implanted drug infusion device, bone growth/fusion stimulator, or cochlear, otologic, or ear implant~10. Tumor that is unlikely to yield adequate tissue for genomic studies in the opinion of the principle investigator

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- All patients (Type: EXPERIMENTAL): All participants enrolled.

Based on this trial design, predict the completion outcome and termination type (if applicable).